High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody

Yves Allenbach 1, 2, * Jeremy Keraen 2 Anne-Marie Bouvier 3 Valérie Jooste 3 Nicolas Champtiaux 2 Baptiste Hervier 2 Yoland Schoindre 2 Aude Rigolet 2 Laurent Gilardin 2 Lucile Musset Jean-Luc Charuel Olivier Boyer 4 Fabienne Jouen 4 Laurent Drouot 4 Jeremie Martinet 4 Tanya Stojkovic 5 Bruno Eymard 5 Pascal Laforêt 5 Antony Behin 5 Emmanuelle Salort-Campana 6, 7 Olivier Fain 8 Alain Meyer 9 Nicolas Schleinitz 10 Kuberaka Mariampillai 1, 2 Aurelie Grados 2 Olivier Benveniste 1, 2
* Auteur correspondant
1 Centre de recherche en myologie
2 Service de médecine interne et d'immunologie clinique [CHU Pitié-Salpêtrière]
3 Registre Bourguignon des Cancers Digestifs
LNC - Lipides - Nutrition - Cancer (U866), CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
4 Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes
5 CHU Pitié-Salpêtrière [APHP]
6 Centre de référence des maladies neuromusculaires et de la SLA
7 GMGF - Génétique Médicale et Génomique Fonctionnelle
8 CHU Saint-Antoine [APHP]
9 Nouvel Hôpital Civil Strasbourg
10 TIMONE - Hôpital de la Timone [CHU - APHM]
Abstract : Cancer occurs frequently in dermatomyositis and is a major cause of mortality. Yves Allenbach et al. report that patients with necrotising auto-immune myopathies also have an increased risk of malignancy, and that myositis-specific antibodies can be used to identify those at greatest risk.Cancer occurs frequently in dermatomyositis and is a major cause of mortality. Yves Allenbach et al. report that patients with necrotising auto-immune myopathies also have an increased risk of malignancy, and that myositis-specific antibodies can be used to identify those at greatest risk.Cancer can occur in patients with inflammatory myopathies. This association is mainly observed in dermatomyositis, and myositis-specific antibodies have allowed us to delineate patients at an increased risk. Malignancy is also reported in patients with necrotizing autoimmune myopathies, but the risk remains elusive. Anti-signal recognition particle or anti-HMGCR antibodies have been specifically associated with necrotizing autoimmune myopathies. We aimed at screening the incidence of cancer in necrotizing autoimmune myopathies. A group of patients (n = 115) with necrotizing autoimmune myopathies with or without myositis-specific antibodies was analysed. Malignancy occurred more frequently in seronegative necrotizing autoimmune myopathies patients and in HMGCR-positive patients compared to anti-signal recognition particle positive patients. Synchronous malignancy was diagnosed in 21.4% and 11.5% of cases, respectively, and incidence of cancer was higher compared to the general population in both groups. No specific type of cancer was predominant. Patients suffering from a synchronous cancer had a decreased median survival time. Cancer screening is necessary in seronegative necrotizing autoimmune myopathies and in HMGCR-positive patients but not in anti-signal recognition particle-positive patients.
Keywords : Reductase Autoantibodies Polymyositis cancer necrotizing autoimmune myopathies auto-antibodies Dermatomyositis Pathological features Inflammatory myopathies
Type de document :
Article dans une revue
Liste complète des métadonnées
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01409979
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : mardi 6 décembre 2016 - 11:58:57
Dernière modification le : lundi 6 janvier 2020 - 17:36:02

Lien texte intégral

openaccess

Identifiants

Collections

UNIV-BOURGOGNE | CNRS | UPMC | U974 | LNC-UMR866 | COMUE-NORMANDIE | ENSBANA | AGROSUP-DIJON | UNIV-AMU | MMG | UNIROUEN | SORBONNE-UNIVERSITE | SU-MEDECINE

Citation

Yves Allenbach, Jeremy Keraen, Anne-Marie Bouvier, Valérie Jooste, Nicolas Champtiaux, et al.. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain - A Journal of Neurology , Oxford University Press (OUP), 2016, 139 (8), pp.2131 - 2135. ⟨10.1093/brain/aww054⟩. ⟨hal-01409979⟩

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

226

Contact

Informations

CCSD